IP Library Patent Application 13915569
Patent Application
App. No. 13/915,569

Cancellous Bone Treated with Collagenase and Essentially Free of Blood Cells

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/915,569
Abstract

A bone implant comprising cancellous bone that is essentially free of blood cells, and which has been treated with at least a loosening agent, such as collagenase and/or a digestive enzyme, for a time and at a concentration to loosen the osteogenic cells in the cancellous bone matrix. The osteogenic cells in the matrix are viable cells. The treatment of the cancellous bone with at least one loosening agent enables the osteogenic cells to be more available for carrying our their osteogenic function and to provide for an increased rate of bone formation.

Claims (9)

1 . A bone implant, comprising:

cancellous bone, said cancellous bone being essentially free of blood cells, said bone having been treated with at least one loosening agent for a time and at a concentration to loosen the osteogenic cells in the cancellous bone matrix, said osteogenic cells in the bone matrix being viable cells.

2 . The implant of claim 1 wherein said at least one loosening agent is selected from the group consisting of collagenase and digestive enzymes.

3 . The implant of claim 2 wherein said at least one loosening agent is collagenase.

4 . The implant of claim 3 wherein said bone is treated with said collagenase at a concentration of from about 0.1 mg/ml to about 3.0 mg/ml.

5 . The implant of claim 4 wherein said bone is treated with said collagenase at a concentration of from about 1.0 mg/ml to about 3.0 mg/ml.

6 . The implant of claim 3 wherein said bone is treated with said collagenase for a period of time from about 5 min. to about 3 hrs.

7 . The implant of claim 6 wherein said bone is treated with said collagenase for a period of time from about 5 min. to about 30 min.

8 . The implant of claim 3 wherein said bone is treated with said collagenase at a concentration of 1.0 mg/ml for 10 minutes.

Assignments (3)
SECURITY INTEREST Recorded Feb 28, 2020
From: NUVASIVE, INC.; NUVASIVE CLINICAL SERVICES MONITORING, INC.; NUVASIVE CLINICAL SERVICES, INC.; NUVASIVE SPECIALIZED ORTHOPEDICS, INC.
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 052918/0595 →
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded May 17, 2017
From: NUVASIVE, INC.; BIOTRONIC NATIONAL, LLC; NUVASIVE CLINICAL SERVICES MONITORING, INC.; NUVASIVE CLINICAL SERVICES, INC.; NUVASIVE SPECIALIZED ORTHOPEDICS, INC.
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 042490/0236 →
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Nov 16, 2016
From: NUVASIVE, INC.; IMPULSE MONITORING, INC.
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 040634/0404 →